Biotechnology

Medeologix Acquires Three Silicon Valley Medical Device CDMO Companies and Establishes One-Stop Shop Mass Production Facilities in Taiwan

NEW TAIPEI CITY, Taiwan, Nov. 28, 2022 /PRNewswire/ -- Medeologix, a Taiwan MedTech CDMO company announces its successful acquisition of three premier medical device manufacturing companies to form an integrated full function service group. The newly formed Medeologix family of companies, with a ...

2022-11-28 21:00 3901

SeekIn Receives CE-IVD Mark Approval for SeekInCure® Cancer Recurrence Monitoring Kit

First-of-its-kind blood-based pan-cancer recurrence monitoring test SHENZHEN, China, Nov. 28, 2022 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE (Conformité Européenne) Mark approval for SeekInCure® Cancer Recurrence Moni...

2022-11-28 21:00 3398

GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2022 Annual Meeting of American Society of Hematology (ASH)

SHANGHAI and NEW ORLEANS, Nov. 28, 2022 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the preliminary safety and efficacy data from the Phase I study of GFH009 monotherapy for treatment ...

2022-11-28 19:00 2532

TELEHEALTH USAGE IN ASIA PACIFIC FOR PEOPLE LIVING WITH HIV INCREASING, BUT DATA PRIVACY AND LACK OF PERSONAL CONTACT STILL SEEN AS A BARRIER TO WIDER USE

- Half of the people living with HIV (PLHIV) and individuals at-risk (IARs) surveyed in the region increased their usage of telehealth services over the past year; this is driven by the availability of new telehealth services during pandemic - Top factor impacting usage of telehealth services fo...

2022-11-28 15:00 2662

Nuance Pharma announces partnership with DKSH to launch Bentrio™ Nasal Spray in Hong Kong and Macau

SHANGHAI, Nov. 28, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces partnership with DKSH Hong Kong (DKSH HK) Business Unit Healthcare to launch BentrioTM nasal spray in Hong Kong and Macau, marking the very first milestone of Nuance Pharma's commercial expansion in the APAC market. U...

2022-11-28 13:40 4232

Innovent Announced Clinical Data of Multiple Trials Will be Presented at the 2022 ESMO-IO and ASH Annual Meetings

ROCKVILLE, Md. and SUZHOU, China, Nov. 28, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology an...

2022-11-28 08:00 3891

Chemotherapy may be completed within 8 days with two doses of Polytaxel, an innovative anticancer drug from South Korea's biotech firm

* Polytaxel, a novel pain-free anticancer drug, may not require break periods * A new standard of care, more convenient than docetaxel, is suggested * Hyundai Bioscience to enter clinical trial on pancreatic cancer in Australia * Patient-centered chemotherapy to enable outpatients to live nor...

2022-11-25 21:00 12195

AstraZeneca Thailand Wins Two ACES Awards 2022: "Industry Champions of the Year" and "Community Initiative"

BANGKOK, Nov. 25, 2022 /PRNewswire/ -- AstraZeneca (Thailand) Co., Ltd., was recently honoured with two accolades in the categories ofIndustry Champions of the Year and Community Initiative at the Asia Corporate Excellence & Sustainability Awards 2022(ACES Awards 2022).

2022-11-25 10:00 3492

Hugel's 'Letybo' First in Korea to Obtain Marketing Approval from Australia

- Obtained marketing approval on the 23rd (local time) from the Therapeutic Goods Administration (TGA) ofAustralia for the indication of glabellar lines - First shipment and local launch planned for Q1 2023...Plans to cooperate with major chain clinics and key opinion leaders SEOUL, South Korea,...

2022-11-24 22:00 4929

AstraZeneca Certified Best Place to Work in Indonesia for 2022

JAKARTA, Indonesia, Nov. 24, 2022 /PRNewswire/ -- AstraZeneca Indonesia, a ffiliate of the multinational pharmaceutical and biopharmaceutical company,was recently recognized as the Best Place to Work in Indonesia for 2022. The company received outstanding scores across several aspects of their wo...

2022-11-24 21:35 4461

Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Nov. 23, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment o...

2022-11-23 21:00 3913

Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDA

--The Phase I clinical trial will consist of 3 cohorts in healthy subjects, including single- and multiple-dose escalation studies and food effect study. The objective of Phase I trial is to find a right dose to move into the pivotal Phase II/III in COVID-19 patients --In antiviral cellular assa...

2022-11-23 19:43 3424

PUBLICATION OF THE OFFERING CIRCULAR IN RELATION TO THE MERGER BETWEEN DSM and Firmenich and the LISTING OF DSM-Firmenich ON EURONEXT AMSTERDAM

THIS PRESS RELEASE IS NOT FOR GENERAL RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO, DIRECTLY OR INDIRECTLY,THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR REGULATIONS This is a joint press relea...

2022-11-22 15:06 2301

3Z: Zebrafish mutant model reveals novel drug candidates for ADHD

REYKJAVIK, Iceland, Nov. 22, 2022 /PRNewswire/ -- ADHD is a highly prevalent neurodevelopmental disorder. The first-line therapeutic for ADHD, methylphenidate, is beneficial for only a subset of patients and can cause side effects including weight loss, insomnia and hypertension. Therefore, the ...

2022-11-22 10:54 2490

Better treatments for breast cancer! Latest Clinical Data of Bispecific Antibodies will be presented at SABCS 2022 By Alphamab Oncology

SUZHOU, China, Nov. 22, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that results from three clinical studies of KN026 (anti-HER2 bispecific antibody) and KN046 (PD-L1/CTLA4 bispecific antibody) will be presented as Spotlight Poster Discussion or Poster Presentation at t...

2022-11-22 09:18 3592

First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy

MELBOURNE, Australia, Nov. 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in a Phase II investigator-initiated study of TLX101 in combination with external beam radiation therapy (EBRT) in patients with rec...

2022-11-22 04:59 2790

Umoja Biopharma and IASO Biotherapeutics Announce Research Collaboration to Bring Off-the-Shelf Therapies to Patients with Hematological Malignancies

Collaboration will bring together Umoja's iCIL platform and IASO's chimeric antigen receptors to create the next generation of broadly accessible, readily available cell therapies in indications that are significantly underserved by today's standards of care. SEATTLE, SAN JOSE, Calif., SHANGHAI ...

2022-11-21 21:00 2211

Immorna Receives IND Clearance to Conduct a Phase 1/2 Study of JCXH-221, a Broadly Protective mRNA-Based COVID-19 Vaccine

MORRISVILLE, N.C., Nov. 21, 2022 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company, focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) a...

2022-11-21 20:00 1632

Cambrex to Acquire Snapdragon Chemistry, a Leader in Continuous Flow API Development Services

EAST RUTHERFORD, N.J., Nov. 21, 2022 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that it has entered into a definitive agreeme...

2022-11-21 19:00 2151

OLON, INTERNATIONAL API SUPPLIER, RELEASES THE NEW SUSTAINABILITY REPORT 2022 CONFIRMING THE PROGRESS OF ITS SUSTAINABILITY IN THE FOCUS AREAS OF ENVIRONMENT, SUPPLY CHAIN, PEOPLE, COMMUNITY ENGAGEMENT, PRODUCTION

"Our ambition is to promote a more sustainable production of APIs, meeting the highest standards of quality"Paolo Tubertini, CEO of the Group, commented "To achieve this, we are investing in people, in innovation and technology processes, endorsing the sustainable development goals proposed by th...

2022-11-21 18:00 2000
1 ... 99100101102103104105 ... 280